Haloperidol Tablets Rx
Generic Name and Formulations:
Haloperidol 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg; scored tabs.
Various generic manufacturers
Indications for Haloperidol Tablets:
Psychosis. Tourette's disorder. For severe behavior disorders or as a short-term treatment for hyperactivity in children who are refractory to psychotherapy or other medications.
Individualize. Initially: Moderate symptoms: 0.5mg–2mg 2–3 times daily. Severe, chronic, or resistant symptoms: 3mg–5mg 2–3 times daily. Debilitated: 0.5mg–2mg 2–3 times daily. Max: 100mg/day.
<3yrs: not recommended. Total dose may be divided, to be given 2–3 times daily. ≥3yrs: initially 0.5mg daily, may increase at increments of 0.5mg at 5–7 day intervals. Psychosis: 0.05mg/kg/day–0.15mg/kg/day. Nonpsychotic behavior and Tourette's: 0.05mg/kg/day–0.075mg/kg/day. Max 6mg/day.
Initially 0.5mg–2mg 2–3 times daily.
Severe CNS depression. Coma. Parkinsonism.
Elderly with dementia-related psychosis (not approved use): increased risk of death. Risk of QT prolongation: electrolyte disturbances (eg, hypokalemia, hypomagnesemia), underlying cardiac abnormalities, hypothyroidism, familial long QT-syndrome, concomitant drugs known to prolong the QT interval. Seizures. Thyrotoxicosis. Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. Severe cardiovascular disorders. Mania. Avoid abrupt cessation. Debilitated. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy. Nursing mothers: not recommended.
CNS depression potentiated with alcohol, other CNS depressants. Possible neurotoxicity with lithium: monitor, discontinue if occurs. Caution with drugs that prolong the QT interval (eg, ketoconazole, paroxetine). May be potentiated by CYP3A4 inhibitors/substrates or CYP2D6 enzymes (eg, itraconazole, nefazodone, buspirone, venlafaxine, alprazolam, fluvoxamine, quinidine, fluoxetine, sertraline, chlorpromazine, promethazine. May be antagonized by CYP3A4 inducers (eg, rifampin, carbamazepine); monitor and adjust doses. May increase intraocular pressure with anticholinergics. Monitor anticoagulants.
Tardive dyskinesia, extrapyramidal symptoms, CNS effects, GI upset, cardiovascular effects, bronchopneumonia, neuroleptic malignant syndrome.
Formerly known under the brand name Haldol.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Examining Associations Between Diabetes and Effects on Cognition
- Untreated Depression Common in Women of Childbearing Age
- Incidence of Psychiatric Disorders in Rheumatoid Arthritis
- Effect of Antidepressant Class, Dose on Pediatric Anxiety Disorders